Mainz Biomed NV (NASDAQ:MYNZ – Get Free Report) shares traded down 3.5% during mid-day trading on Tuesday . The stock traded as low as $1.3503 and last traded at $1.39. Approximately 511,983 shares traded hands during mid-day trading, an increase of 38% from the average daily volume of 371,589 shares. The stock had previously closed at $1.44.
Mainz Biomed Price Performance
The company has a market cap of $12.59 million, a price-to-earnings ratio of -0.02 and a beta of 0.31. The company has a current ratio of 0.52, a quick ratio of 0.43 and a debt-to-equity ratio of 0.44. The company’s 50 day moving average price is $1.53 and its 200 day moving average price is $1.21.
Institutional Investors Weigh In On Mainz Biomed
A number of hedge funds have recently added to or reduced their stakes in MYNZ. Steward Partners Investment Advisory LLC increased its position in Mainz Biomed by 200.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 30,000 shares of the company’s stock worth $34,000 after purchasing an additional 20,000 shares during the period. Cerity Partners LLC purchased a new position in shares of Mainz Biomed during the 4th quarter worth approximately $183,000. Finally, Armistice Capital LLC lifted its holdings in shares of Mainz Biomed by 45.0% in the 2nd quarter. Armistice Capital LLC now owns 285,000 shares of the company’s stock valued at $402,000 after buying an additional 88,400 shares during the period.
About Mainz Biomed
Mainz Biomed AG is a molecular diagnostics company headquartered in Mainz, Germany, specializing in epigenetics-based tests for the early detection of cancer. The company develops proprietary assays that analyze DNA methylation patterns and other epigenetic biomarkers to identify malignancies at a stage when treatment outcomes are most favorable. Mainz Biomed’s technology platform is designed to offer non-invasive, easy-to-use screening solutions that can be deployed both in laboratory settings and at point of care.
The company’s flagship product, ColoAlert®, is a stool-based colorectal cancer screening test that combines DNA methylation markers with bacterial gene targets to improve sensitivity and specificity for detecting advanced adenomas and early-stage colorectal cancer.
Featured Stories
- Five stocks we like better than Mainz Biomed
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
